- News Home
6 March 2014 1:04 pm ,
Vol. 343 ,
Magdalena Koziol, a former postdoc at Yale University, was the victim of scientific sabotage. Now, she is suing the...
Antiretroviral drugs can protect people from becoming infected by HIV. But so-called pre-exposure prophylaxis, or PrEP...
Two studies show that eating a diet low in protein and high in carbohydrates is linked to a longer, healthier life, and...
Considered an icon of conservation science, researchers at World Wildlife Fund (WWF) headquarters in Washington, D.C.,...
The new atlas, which shows the distribution of important trace metals and other substances, is the first product of...
Early in April, the first of a fleet of environmental monitoring satellites will lift off from Europe's spaceport in...
Since 2000, U.S. government health research agencies have spent almost $1 billion on an effort to churn out thousands...
- 6 March 2014 1:04 pm , Vol. 343 , #6175
- About Us
FDA Recruits Bioethicist Charo to Its Top Ranks
6 August 2009 5:23 pm
Bioethics expert R. Alta Charo is joining the U.S. Food and Drug Administration as a senior adviser to FDA Commissioner Margaret Hamburg. In an interview Wednesday, Hamburg said that Charo will be involved in many cutting-edge fields. "I expect that we will quickly make use of her as we think about strategies on how to address the review of products in the arena of personalized medicine, in-vitro diagnostics, stem-cell therapies, where she's already done important work," Hamburg said.
Charo, on the law faculty of the University of Wisconsin, Madison, has written extensively on the ethics of embryonic stem cell research, served on President Barack Obama's FDA transition team, and was a member of President Bill Clinton's bioethics advisory council. Charo's influence at FDA will be "broader than bioethics," said Hamburg."She also is an expert on food and drug law," areas in which her advice will be welcome. The FDA director said that she and her staff are looking forward to working with the National Institutes of Health on establishing a regulatory framework for assessing new medical diagnostics and treatments. "I think that, working together, we will be able to put in place a strategic framework to make sure that the scientific opportunities can translate into available products, with appropriate regulatory review." Charo has said that she hopes to focus on developing a comprehensive approach to regulating genetic tests.